Repertoire Immune Medicines
Latest round
- Series B
Last raised
- Apr 2021
Total raised
- $189M
Investors
- 6
About Repertoire Immune Medicines
Repertoire Immune Medicines, Inc. specializes in the development of immune therapies targeting cancer and autoimmune diseases. The company’s founders are Ewen Cameron and Justin Khanna, while Torben Nissen serves as the CEO.Repertoire Immune Medicines specializes in the development of innovative immune therapies targeting cancer and autoimmune diseases. Central to their offerings is the proprietary DECODE platform, which provides in-depth insights into immune synapses—key components of the adaptive immune system. This technology allows for the identification of unique T cell codes and their interactions, enabling the design of programmable immune medicines tailored to treat a variety of solid and hematological cancers, as well as autoimmune conditions. The company aims to deliver these transformative therapies to healthcare institutions and patients in North America and Europe, with ongoing efforts to penetrate additional global markets.Repertoire Immune Medicines generates revenue through partnerships and collaborations with biopharmaceutical firms and research institutions, focusing on the advancement of their therapeutic candidates. Transactions typically involve contractual agreements for the development and commercialization of their proprietary therapies, which may include milestone payments and royalties tied to product sales. The company’s pipeline includes both flagship and emerging products designed for targeted cancer treatment and the management of autoimmune diseases.In April 2021, Repertoire Immune Medicines, Inc. The company plans to expand its proprietary DECODE discovery platform and accelerate its clinical and preclinical pipeline, along with hiring new teams and enhancing manufacturing capabilities.
Who invested in Repertoire Immune Medicines
6 investors across 2 rounds
See all investors in Repertoire Immune Medicines
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Repertoire Immune Medicines
Who invested in Repertoire Immune Medicines?
Repertoire Immune Medicines has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Repertoire Immune Medicines raised?
Repertoire Immune Medicines has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Repertoire Immune Medicines last raise money?
Repertoire Immune Medicines's most recent round on record is a Series B, in Apr 2021.
What does Repertoire Immune Medicines do?
Repertoire Immune Medicines, Inc.
Where is Repertoire Immune Medicines headquartered?
Repertoire Immune Medicines is headquartered in Cambridge, US.
Which VCs invest in companies like Repertoire Immune Medicines?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Repertoire Immune Medicines's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Repertoire Immune Medicines? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.